ArticleAesthetic plastic surgery2025
A Novel Six-Point Supraperiosteum Injection with Calcium Hydroxyapatite for Jawline Refining and Facial Anti-aging in Asian Patients.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polycaprolactone versus calcium hydroxylapatite injectable treatments in the T-zone for facial rejuvenation: a clinical comparative study.American journal of translational research · 2026Article
- Facial Overfilled Syndrome: A Narrative Clinical Review.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSupraperiosteal injection by calcium hydroxyapatite (CaHA) fillers is an efficient treatment for facial rejuvenation to achieve bony recontouring, facial augmentation and lifting. However, a safe and efficient injection technique for Asians was not described, and an assessment scale to quantify "facial anti-aging" does not exist.
methodsWe enrolled 16 Asian women (n = 32) to receive a single session of six-point calcium hydroxyapatite (CaHA, Radiesse® Plus) filler injections between July 1, 2021, and July 1, 2022. The six injection sites included the eyebrow arch, lateral eyebrow, lateral zygoma, piriform fossa, lateral chin, and anteromedial cheek. Efficacy was assessed at weeks 0 (immediately post-treatment), 4, 12, and 24 using a specialized angular and length measurement system, with outcomes further evaluated using an 11-level anti-aging scale.
resultsAmong the four angular and six linear parameters assessed, statistically significant variations were observed across five time points. Regarding post hoc analyses, the Eyebrow-Tail angle showed a statistically significant change at week 24, increasing by 2.84° (p < 0.001) and corresponding to an anti-aging scale value of 6. This parameter indicated eyebrow lifting. The Tragus-Oral (-10.4 mm, p = 0.004) and Lower Facial Contouring (-9.8 mm, p = 0.044) showed statistically significant reductions and received aging scale ratings of 10 and 9, respectively, at week 24. These two parameters indicated achieving jawline refining. Overall, the final anti-aging scale improved from an average of 50-59, with minimal or ignorable ecchymosis and swelling at week 24.
conclusionsThe 6-point calcium hydroxyapatite filler injection achieved facial rejuvenation. After a single session, the injection recontoured the jawline and lifted the eyebrow tail. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors www.springer.com/00266.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.